We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Napo Pharm.Regs | NAPL | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.35 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.35 | 0.35 |
| Top Posts |
|---|
Posted at 19/5/2008 11:36 by monis Re adjusting NAPU up today. Keeping it in line with us at NAPL I suppose. |
Posted at 31/7/2006 13:50 by currypasty RNS Number:9592GNapo Pharmaceuticals Inc 31 July 2006 For immediate release 31st July 2006 Napo Pharmaceuticals, Inc ("Napo" or "the Company") First Day of Dealings on the Main Market of the London Stock Exchange Napo Pharmaceuticals, Inc., (LSE: NAPL), which focuses on the development and commercialisation of proprietary pharmaceuticals for the global marketplace in collaboration with local partners, today announces that its shares have started trading on the Main Market of the London Stock Exchange. Company highlights: * Napo's late stage proprietary gastro-intestinal compound, crofelemer, is in various stages of clinical development for four distinct product indications. * One product in Phase 3, two in Phase 2 and one in Phase 1 clinical trials * Four indications - AIDS diarrhoea, Irritable Bowel Syndrome (IBS), acute infectious diarrhoea (traveller's diarrhoea and cholera) and paediatric diarrhoea * FDA fast-track status for AIDS diarrhoea and IBS products * Extensive safety data on approximately 1500 patients across all indications * Global business model with multiple corporate partners covering all four clinical indications in all countries * Focus on profitability in Western markets and emerging economy populations for large product volume and financial return * Pipeline product for metabolic syndrome * Strong management and Board experience with more than 10 drug regulatory approvals worldwide * Crofelemer sustainably harvested from medical rainforest plant - benefit sharing contribution in place to recognise indigenous knowledge and environmental responsibility. Placing highlights: * Placing and subscription proceeds of circa. #11.9M before expenses * Placing price of 83 pence per share * Market capitalisation at the placing price of circa. #35.8M * Proceeds of the placing will be used to continue to progress the Company's pipeline including product registration and launches Nomura Code Securities Limited is acting as the sponsor, financial adviser and broker. Ms Lisa Conte, Chief Executive Officer of Napo Pharmaceuticals Inc, commented: "As a global business we are delighted to join the Main Market of the London Stock Exchange today. We have a strong and late-stage pipeline and will use the proceeds of this placing to develop our products which will address large and profitable western indications as well as global health needs afflicting huge populations in emerging and developing economies. These activities will generate multiple revenue streams from around the world." For more information please contact: Napo Pharmaceuticals, Inc Lisa Conte, Chief Executive Officer (001) + 650 616 1902 www.napopharma.com Buchanan Communications +44 (0) 20 7466 5000 Tim Anderson, Mary-Jane Johnson, Amy Rajendran Nomura Code Securities Limited Juliet Thompson +44 (0) 207 776 1204 Disclaimer The Shares referenced in this announcement are not for distribution, directly or indirectly, in or into the United States or to any US person as defined in Regulation S under the US Securities Act of 1933, as amended ("Regulation S"). This announcement is not an offer of securities for sale into the United States or elsewhere. The Shares described above have not been registered under the US Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold in the United States or to, or for the account or benefit of, US persons (as such term is defined in Regulation S) unless they are registered under the Securities Act or they are exempt from registration under the Securities Act. No offer or sale of Regulation S securities has been made or will be made in the United States. Hedging transactions involving these securities may not be conducted unless in compliance with the Securities Act. |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
